NeuroOne Medical Technologies Corporation (NMTC)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in NeuroOne Medical Technologies Corporation, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

NeuroOne Medical Technologies Corporation (NMTC) has returned 2.44% so far this year and -8.67% over the past 12 months.

Based on dividend-adjusted daily data since Sep 18, 2017, NMTC's average daily return is +0.09%, while the average monthly return is +0.33%. At this rate, your investment would double in approximately 17.5 years.

Historically, 43% of months were positive and 57% were negative. The best month was Aug 2022 with a return of +116.1%, while the worst month was Mar 2022 at -45.0%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 7 months.

On a daily basis, NMTC closed higher 43% of trading days. The best single day was Feb 25, 2019 with a return of +51.9%, while the worst single day was Mar 28, 2022 at -46.9%.

NeuroOne Medical Technologies Corporation has an annualized alpha of 15.42%, beta of 0.63, and R² of 0.01 versus S&P 500 Index. Calculated based on daily prices since September 20, 2017.

• This stock participated in 131.94% of S&P 500 Index downside but only -19.92% of its upside — more exposed to losses than it benefited from rallies.
• Beta of 0.63 may look defensive, but with R² of 0.01 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.01 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

NMTC ranks 38 for risk / return — below 38% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for NeuroOne Medical Technologies Corporation (NMTC) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the NeuroOne Medical Technologies Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the NeuroOne Medical Technologies Corporation was 98.41%, occurring on Apr 9, 2025. The portfolio has not yet recovered.

The current NeuroOne Medical Technologies Corporation drawdown is 97.12%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of NeuroOne Medical Technologies Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how NeuroOne Medical Technologies Corporation is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.